Clinical Trials Logo

Clinical Trial Summary

Pregnant women who admitted with the complaint of amniotic fluid leakage between the gestational ages of 23+0 and 33+0 and who finally were diagnosed as PPROM were included in the study. Women with multiple gestations, cervical dilatation above 6 cm at the admission, hypertensive diseases, cervical cerclage, fetal anomalies, olgohydramnios, polihydramnios, and those who declined to involve in the study were excluded.

In all included women were examined at the admission for amniotic fluid index via trans abdominal ultrasonography. AFI were measured by four quadrant technique, which is sum of the deepest vertical length of pocket of fluid in each quadrant without any umbilical cord. All included patients were assessed in two groups; women with AFI<5 and those with AFI≥5 cm.

Included patients were followed in terms of maternal and fetal complications. Maternal complications were chorioamnionitis, placental abruption, placental retention, postpartum endometritis, postpartum hemorrhage; while fetal complications comprised necessity of admission to neonatal intensive care unit, neonatal sepsis, meconium aspiration syndrome, respiratory distress syndrome, intraventricular hemorrhage, umbilical cord pH below 7.10, APGAR score of 5th minute below 5. All complication rates were compared between the groups. In addition, the time period between the diagnosis of PPROM and the time of delivery was defined as latency period and were compared between the groups.


Clinical Trial Description

Pregnant women who admitted with the complaint of amniotic fluid leakage between the gestational ages of 23+0 and 33+0 were examined for the inclusion criteria of the study. Among them, women with usual history of gross amniotic fluid leakage as well as classical speculum findings of ROM, such as pooling of amnitotic fluid within the posterior fornix or vaginal wall, were diagnosed as PPROM and included in the study without any further investigation. In case of the absence of these findings and suspected cases, PPROM was diagnosed via placental alpha-microglobulin-1 test from the vaginal fluid. Those with positive test results were included in the study. Women with multiple gestations, cervical dilatation above 6 cm at the admission, hypertensive diseases, cervical cerclage, fetal anomalies, olgohydramnios, polihydramnios, and those who declined to involve in the study were excluded.

In all included women were examined at the admission for amniotic fluid index via trans abdominal ultrasonography. AFI were measured by four quadrant technique, which is sum of the deepest vertical length of pocket of fluid in each quadrant without any umbilical cord. All included patients were assessed in two groups; women with AFI<5 and those with AFI≥5 cm.

Included patients were followed in terms of maternal and fetal complications. Maternal complications were chorioamnionitis, placental abruption, placental retention, postpartum endometritis, postpartum hemorrhage; while fetal complications comprised necessity of admission to neonatal intensive care unit, neonatal sepsis, meconium aspiration syndrome, respiratory distress syndrome, intraventricular hemorrhage, umbilical cord pH below 7.10, APGAR score of 5th minute below 5. All complication rates were compared between the groups. In addition, the time period between the diagnosis of PPROM and the time of delivery was defined as latency period and were compared between the groups. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04100252
Study type Observational
Source Istanbul Medeniyet University
Contact
Status Completed
Phase
Start date September 1, 2018
Completion date September 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04478942 - PROMMO Trial: Oral Misoprostol vs IV Oxytocin Early Phase 1
Recruiting NCT02819570 - Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes Phase 4
Withdrawn NCT03172858 - Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices N/A
Not yet recruiting NCT05134688 - Magnesium Sulphate in Premature Rupture of Membranes Early Phase 1
Not yet recruiting NCT03689062 - Premature Rupture of Membranes at 34 to 37 Weeks' Gestation N/A
Recruiting NCT06273891 - Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes Phase 3
Recruiting NCT04237142 - Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL) N/A
Recruiting NCT04558996 - Spanish Registry of Pregnant Women With COVID-19
Recruiting NCT04632017 - Computerized Cardiotocography Monitoring of Fetuses With pPROM
Recruiting NCT03607929 - HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor N/A
Completed NCT03491826 - Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)
Enrolling by invitation NCT04451109 - Dilapan-S®: A Multicenter US E-registry
Recruiting NCT04143685 - Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes N/A
Completed NCT03251898 - Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections
Completed NCT03106311 - The Use of Quantitative Pregnancy Test in Amniotic Fluid as a Diagnostic Tool for Rupture of Fetal Membranes N/A